Sanofi is to hand back the rights to Sangamo Therapeutics’s gene-edited cell therapy for sickle cell disease (SCD), SAR445136, after deciding to focus instead on allogeneic cell therapies.
The Paris-headquartered pharma company announced on 6 January that it would return the rights to the candidate during the first...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
